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3%. The cost-effectiveness ratio was expressed as cost of
life year gained with RSV prophylaxis. Sensitivity analy-
ses were performed for the key probabilities. RESULTS:
Palivizumab prophylaxis was estimated to cost €8903 per
life gained as compared to €6594 for no preventive treat-
ment. The incremental cost-effectiveness ratio of one life
year gained amounted to €13,246 (PPP: €1 = 1.9 PLN).
The sensitivity analysis indicated that the results were sen-
sitive to the probability of hospitalization for RSV for 
no prophylaxis. CONCLUSIONS: Palivizumab, as com-
pared to other widely accepted medical procedures,
appeared to be cost-effective prophylaxis for the preven-
tion of serious lower respiratory-tract infection caused by
RSV in infants born at less than 32 weeks gestation in
Poland.
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OBJECTIVES: The objective is to discuss and evaluate
potential changes in patient, physician, and organisa-
tional behavior related to the introduction of a new health
care technology (treatment of inﬂuenza with the anti-viral
neuraminidase inhibitors). The changes evaluated are: 1)
increased health care seeking by patients, due to the avail-
ability of antivirals for inﬂuenza; 2) Crowding out of
inappropriate anti-biotic prescribing for inﬂuenza by
antivirals; and 3) System change to allow telephone nurse
prescribing rather than GP consultation. METHODS:
Some unique characteristics of neuramindase inhibitors
has important implications for their cost-effectiveness 
in any given health care systems. A health economic 
decision model is employed in order to evaluate some of
these potential changes when introducing treatment of
inﬂuenza with neuraminidase inhibitors. The impact on
cost-effectiveness and cost-utility of three different behav-
ioural changes are investigated with the model as well as
the base line cost-effectiveness and cost-utility of treating
healthy adults in UK. RESULTS: The results of the eco-
nomic modeling show that treatment of inﬂuenza in
healthy adults with the anti-viral oseltamivir has incre-
mental cost-utility ratios between £4,775/QALY (base-
line) and £15,772/QALY (increased health care seeking
by patients). CONCLUSION: In order to make a deci-
sion regarding introduction of inﬂuenza treatment with
the new technology a number of issues ought to be
addressed. These may be best dealt with in a full HTA
where all aspects of introducing a new technology are
investigated. By only evaluating certain aspects of the
introduction of the technology, decision makers are likely
to make decisions based on incomplete information. This
may result in sub-optimal patient treatment and resource
use in society.
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OBJETIVE: The hepatitis C treatment with conven-
tional interferon monotherapy has been under discussion
because of its low response rate (10–20%). However,
combination therapies involving ribavirin and the new
two pegylated interferons have raised the response rates
beyond 50%. This study analyses the cost-effectiveness
ratios for two different peginterferons (peginterferon alfa-
2a and peginterferon alfa-2b) plus ribavirin compared
with interferon-alfa 2b plus ribavirin. METHOD: A
Markov model was developed to represent the natural
history of hepatitis C and to estimate the incremental
cost-effectiveness ratios for the two different peginterfer-
ons plus ribavirin compared with interferon-alfa 2b plus
ribavirin. The results of two indipendent clinical trials
comparing these treatment alternatives in naive patients
with HCV infection and no co-morbidity have been
obtained from several publications. The model was
applied separately to both trials. To evaluate the natural
history of decompensated cirrhosis, 200 patients with
decompensated liver disease from hepatitis C etiology
were studied depending on the ﬁrst decompensation event
in two different hospitals in Spain. RESULTS: The results
indicate costs of €20,751/life-year gained using efﬁcacy
data from the peginterferon alfa-2b trial and €10,350/life-
year gained employing the peginterferon alfa-2a trial
data. When a test is used at 12 weeks to facilitate an early
detection of non-responders, the ﬁgures lower to €14,037
and €6,605/life-year gained, respectively. CONCLU-
SION: The main conclusion is that the combined treat-
ment of peginterferon plus ribavirin is cost-effective
showing peginterferon alfa-2a a better cost-effectiveness
ratio than peginterferon alfa-2b. Efﬁciency decreases with
advancing age and can be increased when strategies of
early selection are employed to identify those patients
who, without sustained viral response, would not beneﬁt
from the treatment.
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